文献速递心律失常血脂与心血管预防

卒中风险与房颤持续时间及CHA2DS2-VASc评分的关系

Stroke Risk as a Function of Atrial Fibrillation Duration and CHA2DS2-VASc Score.
PubMed 文献 · Circulation · 2019-09-30

结果显示两者均显著相关(P<0.001),且风险交互可进一步分层,或有助于指导抗凝治疗。

要点

  • 房颤持续时间和CHA2DS2-VASc评分均与SSE年化风险显著相关(P<0.001)。
  • CHA2DS2-VASc评分0-1时,无论房颤持续时间,SSE风险均低。
  • 评分2且房颤>23.5小时、评分3-4且房颤>6分钟、评分≥5即使无房颤,SSE风险超过1%/年。

核心结论

  • 房颤持续时间与CHA2DS2-VASc评分存在交互作用,可进一步对房颤患者进行SSE风险分层,可能有助于指导抗凝治疗。

主要发现

  • CHA2DS2-VASc评分0-1的患者无论设备检测的房颤持续时间如何,SSE发生率均低。
  • CHA2DS2-VASc评分2且房颤>23.5小时、评分3-4且房颤>6分钟、评分≥5即使无房颤的患者,SSE风险超过可干预阈值(>1%/年)。

关键数值与推荐

  • 可干预阈值定义为SSE年化风险>1%/年。
  • CHA2DS2-VASc评分0-1:无论房颤持续时间,SSE风险低。
  • CHA2DS2-VASc评分2且最大每日房颤负担>23.5小时:SSE风险>1%/年。
  • CHA2DS2-VASc评分3-4且最大每日房颤负担>6分钟:SSE风险>1%/年。
  • CHA2DS2-VASc评分≥5:即使无房颤,SSE风险>1%/年。

临床怎么用

  • 对于设备检测到房颤的患者,应结合房颤持续时间和CHA2DS2-VASc评分综合评估SSE风险。
  • CHA2DS2-VASc评分0-1的患者,即使存在设备检测的房颤,SSE风险仍低。
  • CHA2DS2-VASc评分2且房颤>23.5小时、评分3-4且房颤>6分钟、评分≥5即使无房颤,SSE风险超过1%/年,可考虑抗凝治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Studies of patients with cardiovascular implantable electronic devices show a relationship between atrial fibrillation (AF) duration and stroke risk, although the interaction with CHA2DS2-VASc score is poorly defined. The objective of this study is to evaluate rates of stroke and systemic embolism (SSE) in patients with cardiovascular implantable electronic devices as a function of both CHA2DS2-VASc score and AF duration. METHODS: Data from the Optum electronic health record deidentified database (2007-2017) were linked to the Medtronic CareLink database of cardiovascular implantable electronic devices capable of continuous AF monitoring. An index date was assigned as the later of either 6 months after device implantation or 1 year after electronic health record data availability. CHA2DS2-VASc score was assessed using electronic health record data before the index date. Maximum daily AF burden (no AF, 6 minutes-23.5 hours, and >23.5 hours) was assessed over the 6 months before the index date. SSE rates were computed after the index date. RESULTS: Among 21 768 nonanticoagulated patients with cardiovascular implantable electronic devices (age, 68.6±12.7 years; 63% male), both increasing AF duration (P<0.001) and increasing CHA2DS2-VASc score (P<0.001) were significantly associated with annualized risk of SSE. SSE rates were low in patients with a CHA2DS2-VASc score of 0 to 1 regardless of device-detected AF duration. However, stroke risk crossed an actionable threshold defined as >1%/y in patients with a CHA2DS2-VASc score of 2 with >23.5 hours of AF, those with a CHA2DS2-VASc score of 3 to 4 with >6 minutes of AF, and patients with a CHA2DS2-VASc score ≥5 even with no AF. CONCLUSIONS: There is an interaction between AF duration and CHA2DS2-VASc score that can further risk-stratify patients with AF for SSE and may be useful in guiding anticoagulation therapy.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Kaplan RM, Koehler J, Ziegler PD, et al. Stroke Risk as a Function of Atrial Fibrillation Duration and CHA2DS2-VASc Score. Circulation. 2019. PMID: 31564126. doi:10.1161/CIRCULATIONAHA.119.041303

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。